A B S T R A C T
Background. Renal function in patients with chronic kidney disease (CKD) may follow different trajectory profiles. The aim of this study was to evaluate and illustrate the ability of the latent class linear mixed model (LCMM) to identify clinically relevant subgroups of renal function trajectories within a multicenter hospital-based cohort of CKD patients. Methods. We analysed data from the NephroTest cohort including 1967 patients with all-stage CKD at baseline who had glomerular filtration rate (GFR) both measured by 51 Cr-EDTA renal clearance (mGFR) and estimated by the CKD-EPI equation (eGFR); 1103 patients had at least two measurements. The LCMM was used to identify subgroups of GFR trajectories, and patients' characteristics at baseline were compared between the subgroups identified. Results. Five classes of mGFR trajectories were identified. Three had a slow linear decline of mGFR over time at different levels. In the two others, patients had a high level of mGFR at baseline with either a strong nonlinear decline over time (n ¼ 11) or a nonlinear improvement (n ¼ 94) of mGFR. Higher levels of proteinuria and blood pressure at baseline were observed in classes with either severely decreased mGFR or strong mGFR decline over time. Using eGFR provided similar findings. Conclusion. The LCMM allowed us to identify in our cohort five clinically relevant subgroups of renal function trajectories. It could be used in other CKD cohorts to better characterize their different profiles of disease progression, as well as to investigate specific risk factors associated with each profile.
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I N T R O D U C T I O N
Renal function in patients with chronic kidney disease (CKD) most often progressively decreases over time. However, the rate of decline may be highly variable among patients. For example, O'Hare et al. [1] identified four distinct trajectory profiles of estimated glomerular filtration rate (eGFR) in the 2 years before long-term dialysis initiation in Veterans Affairs patients. They found that 62.8% of patients had a persistently low level of eGFR, while 24.6, 9.5 and 3.1% had progressive, accelerated or catastrophic eGFR decline, respectively. A substantial number of patients may also have an improvement of their renal function [2] [3] [4] [5] . A variety of mechanisms may be involved with the different patterns of progression, with modifiable or nonmodifiable factors associated with evolution of the disease, including underlying primary renal disease [6] . Identification of trajectories of renal function in CKD patients might thus be useful to provide a more nuanced picture of disease progression, which may ultimately contribute to guiding the care of CKD patients [7] . Yet, only few studies have attempted to identify subpopulations of patients with distinct profiles of renal function trajectories over time. Recent advances in statistical methods and software provide an opportunity to achieve this objective. 
marker over time. One of them is the latent class linear mixed model (LCMM), also called growth mixture modelling [8] [9] [10] . The LCMM is an extension of the standard linear mixed model [11, 12] for handling various subpopulations of longitudinal trajectories. Instead of modelling trajectories in subgroups of patients that are a priori defined from their observed characteristics, this approach captures all the heterogeneity in individual trajectories and identifies subgroups of patients with similar profiles of trajectories, independently of observed patient's characteristics. It is also an extension of the latent class growth analysis [13, 14] that has been used in O'Hare et al. [1] , to account for correlation between repeated measures of the same patient. Indeed, not accounting for such correlation usually leads to unreliable confidence intervals, and may in addition induce an overestimation of the number of subpopulations [15] . For all these reasons, the LCMM seems to be a method of choice. However, while the LCMM has already been used to identify subgroups of trajectories of depressive symptoms [16] , for example, its ability to identify subgroups of trajectories of renal function in CKD patients has never been demonstrated.
Our aim was thus to evaluate and illustrate the ability of the LCMM to identify clinically relevant subgroups of renal function trajectories over time in patients with CKD. For this purpose, we used it to identify subgroups of trajectories in a multicentre hospital-based cohort, and we explored the clinical relevance of the subgroups identified as well as the robustness of results in sensitivity analyses.
M A T E R I A L S A N D M E T H O D S

Population
The NephroTest study [17] is a prospective multicentre hospital-based cohort that included 1967 CKD patients from 1 January 2000 to 31 December 2012. To be included, patients had to have CKD stages 1-5 and be referred by nephrologists to any of three physiology departments for extensive workups including measure of GFR (mGFR) by 51 Cr-EDTA renal clearance and further followed-up [2, 17] . Patients on dialysis or living with a kidney transplant and pregnant women were excluded. All patients signed informed consent before inclusion in the cohort. Annual assessments of both mGFR and eGFR using the CKD-EPI equation [18] were performed until the occurrence of death, dialysis initiation, pre-emptive transplantation, loss of follow-up or 31 December 2012, whichever came first. A total of 5142 mGFR measures were available, and 1103 patients had at least two. We graphically examined residuals from a standard linear mixed model to identify outliers in mGFR measures and excluded five potentially incorrect mGFR values after further examination by two independent nephrologists.
Statistical analysis
Identification of subpopulations of distinct mGFR trajectories over time. We used the LCMM implemented in the 'lcmm' R package [19] to identify subgroups of mGFR trajectories over time. The LCMM is an extension of the standard linear mixed model [20] , and thus requires neither the same number of GFR measures per patient, nor that these measures are taken regularly or at the same time points for all patients. It also allows accounting for patients with only one GFR measure at baseline to reduce selection bias [21] . Indeed, because most patients with a single measure have lower baseline mGFR values and are more rapidly dialysis-dependent after inclusion, excluding them from the analysis may induce an overestimation of the mean baseline mGFR level in the population. Therefore, we used all 1967 patients from the cohort, including 864 patients with a single measure of GFR at baseline.
The LCMM was made of two joint submodels, i.e. a multinomial logistic regression model and a linear mixed model. The mathematical representation of these submodels, as well as R codes, is provided in Supplementary Appendix 1, although they are not required to understand the article.
The multinomial logistic regression model expressed the probability for each patient of belonging to each subgroup of trajectories. The subgroups are called 'latent' classes because they are not directly observed in the data. The probability of belonging to a subgroup may depend on patient's characteristics, but we did not introduce any in the model because our aim was to identify latent classes independently of these characteristics. Patients' characteristics within each identified latent class (subgroup) were investigated in a second step as further explained.
The linear mixed model was specific to each latent class where it expressed the observed mGFR value of each patient at a specific time point as the sum of (i) the expected value (i.e. mean) of mGFR at that time in the class, and (ii) the individual patient's departure from that expected value of mGFR. The expected value depended on quadratic functions of time to allow nonlinear mean trajectories over time (spline functions did not suggest more complex trajectories), and did not incorporate any patient's characteristics. Individual departures from the mean trajectory of each class were represented by random effects (a random intercept, a random effect on time and a random effect on time-squared) with class-specific variance and random errors (see Supplementary Appendix 1).
To choose the optimal number of latent classes, we estimated five LCMMs with one to five classes each, and we selected the model that provided the best fit to data according to the Bayesian Information Criterion (BIC) [22] . From the selected LCMM, we calculated for each patient the posterior probability that he/she belongs to each class, and a posteriori we classified him/her in the class for which he/she had the highest probability of belonging. The ability of the model to discriminate between the different identified classes of trajectories was then assessed by inspecting the posterior classification table (see Supplementary Appendix 1).
Patients' characteristics in each subgroups of trajectories. To assess the clinical relevance of the subgroups of trajectories identified, we compared the following patient characteristics at baseline between each class: age (in years), protein-creatinine ratio (PCR), CKD stage, presence of diabetes, hypertension (stratified in four classes: blood pressure < 140/90 mmHg without treatment, blood pressure 140/90 mmHg without treat-
ment, blood pressure <140/90 mmHg with treatment, blood pressure 140/90 mmHg with treatment), cardiovascular history (defined as a history of stroke, ischaemic heart disease or heart failure), type of nephropathy (diabetic nephropathy, glomerular nephropathy, vascular nephropathy, polycystic renal disease, tubular interstitial nephritis, other), number of mGFR assessments, length of follow-up (in years), gender and ethnicity (African origin or not).
Sensitivity analyses.
Because previous studies have restricted the investigation of renal function trajectories to patients with at least two measures of renal function [1] [2] [3] , we repeated our analysis in the 1103 patients with at least two mGFR measures [21] .
In a second sensitivity analysis, instead of modelling trajectories of current values of mGFR, we modelled the absolute change of mGFR over time, defined by the difference between the current value of mGFR at each visit and the value of mGFR at baseline. This analysis was also based on the 1103 patients with at least two mGFR measures.
Finally, because eGFR is more routinely used than mGFR, we repeated our analyses using repeated values of eGFR rather than mGFR, in the 1963 patients who had at least one CKD-EPI eGFR assessment among the 1967 patients included in the main analysis.
R E S U L T S
The characteristics of the 1967 patients are shown in Table 1 . In the 1103 (56.1%) patients with more than one mGFR assessment, the time elapsed between the first and last mGFR assessments ranged from 6 months to 12.4 years with a median of 3.2 years.
Subgroups of mGFR trajectories
In our main analysis including the 1967 patients, the best fit to data was obtained with five latent classes (model M1). L a t e n t c l a s s m i x e d m o d e l a n d m G F R t r a j e c t o r i e s ii187
Estimated mean trajectories are shown in Figure 1 . In two classes, patients had a high mGFR value at inclusion (mean of 63.7 and 70.0 mL/min/1.73 m 2 for Classes 1 and 2, respectively) with either a strong nonlinear decline of mGFR over time (Class 1 'strong decline', n ¼ 11, 0.6%) or a nonlinear improvement of mGFR in Class 2 ('improvement', n ¼ 94, 4.8%). In the three other classes, the mean trajectory was nearly linear with a slow rate of mGFR decline at different levels. In Class 3 ('slow decline at high level', n ¼ 820, 41.7%), patients had a high level of mGFR with a mean baseline value of 52.4 mL/min/1.73 m 2 . In Class 4 ('slow decline at moderate level', n ¼ 744, 37.8%), patients had a moderate level of mGFR with a mean baseline value of 32.1 mL/min/1.73 m 2 . In Class 5 ('slow decline at severe level', n ¼ 298, 15.1%), patients had a severe level of mGFR with a mean baseline value of 18.1 mL/min/1.73 m 2 . The individual trajectories within each class are shown in Figure 2 . The variability between trajectories was more important in the classes with the highest mGFR level (Classes 1, 2 and 3) than in the class with the lowest mGFR level (Class 5), which is consistent with the parameter estimates that were obtained for the class-specific variance of random effects of the linear mixed model (see Supplementary Appendix 1) .
Model M1 had a good discrimination ability overall, although patients a posteriori classified in Class 5 with the most severe level of mGFR had a mean probability of 25% of belonging to Class 4 with moderate level (see posterior classification in Supplementary Appendix 1) . This might be due to the fact that the proportion of patients with one or two measures only was more important in Class 5 
Patient's characteristics in each subgroups of trajectories
Patients a posteriori classified in the classes with high baseline mGFR followed by either a strong decline (Class 1) or an improvement (Class 2) were on average younger than those in the classes with slow rates of decline (Table 2 ). Men and patients of African origin were more frequent in classes with higher mean baseline mGFR (Classes 1, 2 and 3) . The proportion of patients with glomerular nephropathy was the highest in the class with high mean baseline mGFR followed by a strong decline (Class 1). The proportion of patients with diabetes, cardiovascular history, and diabetic or vascular nephropathy was higher in the classes with slow mGFR decline at moderate (Class 4) or severe (Class 5) level. The proportion of patients with uncontrolled hypertension (blood pressure 140/ 90 mmHg with treatment) was the highest in the class with strong mGFR decline (Class 1) and in the classes with a slow decline at severe or moderate level of mGFR (Classes 4 and 5). Classes 1 ('strong decline') and 5 ('slow decline at severe level') had the highest PCR medians with, respectively, 70 and 120 mg/ mmol.
Sensitivity analyses
When we restricted the analysis to the 1103 patients with at least two mGFR assessments, the best LCMM (model M2) identified four latent classes (Figure 3 ) that were similar to those obtained in our main analysis. In two classes, patients had a high baseline mGFR (mean of 55.1 and 61.9 mL/min/1.73 m 2 for Classes 1 and 2, respectively) with a strong nonlinear decline of mGFR over time in Class 1 ('strong decline', n ¼ 11, 1.0%) and a nonlinear improvement of mGFR in Class 2 ('improvement', n ¼ 34, 3.1%). Patients classified a posteriori in these two classes had been classified in the same classes as in model M1 using all patients (Table 3 ). The two other classes had a mean trajectory that was nearly linear, with a slow decline rate over time at different levels (mean baseline mGFR of 48.7 and 27.8 mL/min/1.73 m 2 in Classes 3 and 4, respectively). Most of the 549 patients who were a posteriori classified in Class 3 with the slow decline at high level were classified in the same class as in the main analysis using all patients and based on model M1 (Table 3) . Over the 509 patients a posteriori classified in Class 4 with the slow decline at moderate level, 359 were classified in the same class as in the main analysis, and 150 were classified in Class 5 of the main analysis (Table 3) . Excluding patients with a single mGFR measure at baseline thus prevented us from further distinguishing this class of patients with severe mGFR level.
When we used the absolute change in mGFR from baseline as the outcome variable in the linear mixed model (rather than the current value of mGFR), the best LCMM (model M3) identified three latent classes only (Figure 4) . However, the results were similar to the two previous analyses using current mGFR values, since 1052 (95.4%) patients were a posteriori classified in a class with a slow linear decline of mGFR over time (Class 3). The two other small Classes 1 and 2 were also similar as those (Table 3) .
When we used eGFR instead of mGFR in all patients, the best fit to data was obtained with five latent classes (model M4, Figure 5 and Figure 1S in Supplementary Appendix 2) that were similar to those obtained with mGFR ( Figure 1) . The characteristics of patients a posteriori classified in these five classes were also similar to in our main analysis, with for example the youngest patients in Classes 1 and 2, and the highest level of PCR at baseline in Classes 1 and 5 (Table 7S in Supplementary Appendix 2). The most important difference between the two series of results was for Class 2 of improvement, which had a mean trajectory with a much less pronounced improvement when using eGFR rather than mGFR. This resulted in a much larger number of patients a posteriori classified in the class of improvement when using eGFR than when using mGFR (263 versus 94), and thus also a reduced number of patients a posteriori classified in Class 3 with a slow decline at high level (696 versus 820). 
D I S C U S S I O N
Our study illustrates how subgroups of trajectories of renal function can be identified using the LCMM, without making any prior assumption on the number and types of longitudinal profiles. In all analyses, we had consistent results with most patients in our population classified as having a slow linear decline of mGFR irrespective of their baseline mGFR value and despite the quadratic function of time in the model. The LCMM also allowed us to identify two small subgroups of patients with high baseline mGFR values followed by either a strong nonlinear decline or, on the contrary, a nonlinear improvement of mGFR. Few other studies also described patients with an improvement of renal function [3, 23] . In a previous analysis of a subsample of the NephroTest cohort that included 406 patients who had at least three mGFR measures and 2 years of follow-up in two of the three physiology departments, patients were classified as improvers (15.3%) or nonimprovers (81.8%) by four nephrologists according to observed individual mGFR trajectories [2] . The use of LCMM yielded a much lower proportion of improvers (4.8% when all patients were included and 3.1% when patients with a single measure were excluded). The discrepancy of results may partly be due to the fact that the LCMM makes no prior assumption on the number of classes and on the expected trajectories within these classes, as opposed to an approach based on clinical judgment of experts. In addition, the LCMM allowed us to use all information on all patients, including those with a single mGFR measure at baseline. As mentioned in the Materials and methods section, excluding them could lead to an over-estimation of the mean baseline level, because they had lower baseline mGFR and were more likely to require dialysis rapidly after inclusion. This may explain why we could not identify the class with the most severe level of Figure 1 ) after exclusion of patients with a single mGFR measure (Figure 3) . However, our sensitivity analyses suggest that excluding these patients may not necessarily result in substantial differences in the findings of the LCMM since the two small classes of patients with strong nonlinear decline and nonlinear improvement of renal function were identified in all analyses. The mean improvement of renal function was however much less pronounced when using eGFR than mGFR. Although the CKD-EPI equation was shown to perform generally well over time [24] , a possible explanation may be that it may underestimate high values of renal function [18] . While the subgroups of trajectories identified, as well as their distribution, might be specific to our cohort, comparison of most patients' characteristics between classes provided expected results from a clinical perspective, which may be an indication of the appropriateness of the use of the LCMM to identify distinct trajectories of renal function in a specific population. For example, we found that the mean age at baseline was lower (<50 years old) in the classes with a high baseline level of mGFR followed by either a strong decline (Class 1) or an improvement of mGFR (Class 2). While it is not surprising that younger patients at baseline are those with the highest baseline mGFR values, it may be interesting to note that the renal function of these young patients may either strongly decrease or increase. Age thus does not seem to explain the difference in further evolution of mGFR. This confirms previous studies that compared characteristics between improvers and nonimprovers and found no association with age [2, 3, 23] . Evolution of mGFR is more likely related to the type of nephropathy. For example, we observed the highest proportion of patients with glomerular nephropathy in the class with the fastest decline of mGFR (Class 1), probably because of the worse prognosis of this type of nephropathy. As glomerular nephropathy is earlydiagnosed because of clinical symptoms, it is also consistent to observe a higher proportion of this type of nephropathy in a class of young patients. The higher proportion of women in the class with low mGFR level (Class 5) than in the classes with higher level (Classes 1, 2 and 3) may just indicate that women tended to be included in the NephroTest cohort at a later CKD stage than men. However, all comparisons of patients' characteristics at baseline should be taken with caution since they were not adjusted for potential confounders. While such adjustment could be performed using a multinomial logistic regression model, we did not do it because of too small sample sizes in some identified latent classes (n ¼ 11 patients a posteriori classified in the class with a strong decline). Our study has several limitations. In our model, we used a quadratic function of time to model mGFR trajectories. The estimated shape of the mean trajectories was thus influenced by this assumption. As we said in the Materials and methods section, the 'lcmm' R package handles splines functions of time, but a series of preliminary analyses of our data using these more flexible functions of time did not suggest more complex mean trajectories than quadratic functions of time. We thus used quadratic functions of time in all analyses, which could be estimated with our data because of a sufficient number of patients with four or more annual mGFR measures.
A limitation of the LCMM is that it assumes that patients who drop out from the study early do it for reasons that are either unrelated to renal function (data 'missing completely at random'-MCAR), or only related to values of renal function 'observed' before dropout (data 'missing at random'-MAR). Linear mixed models, and by extension the LCMM, are robust to such missing data. However, if the reason for dropout might be related to 'unobserved' values of the renal function (data 'missing not at random'-MNAR), then the analysis should account for such informative dropout. Potential informative dropout due to dialysis, transplantation or death can be accounted for in joint models. A joint LCMM [25] is implemented in the 'lcmm' R package, but the estimation of it with our data did not achieve criterion of convergence, probably because of too small numbers of events in some classes. However, recent studies found similar results between a standard longitudinal model for repeated eGFR measures and a joint shared random effects model accounting for dropout due to initiation of renal replacement therapy or death [26, 27] . Although these results did not allow identification of subgroups of trajectories because the joint model was based on shared random effects rather than on latent classes, they suggest that dropout due to dialysis, transplantation or death is unlikely to be a source of informative censoring in CKD patients.
In conclusion, we believe that the LCMM is an interesting advanced statistical tool to identify distinct subgroups of renal function trajectories over time, as well as characteristics associated with identified subgroups. While some of the results that we found might be specific to our cohort of CKD patients, we believe that the subgroups identified provide a clinically relevant description of the different profiles of disease progression existing in that cohort. It would be of particular interest to further use the LCCM in different populations of CKD patients, in order to provide a more nuanced picture of disease progression within the wide heterogeneous population of CKD patients. 
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